Home Current Issue Previous Issues Podcasts Online First ASA Practice Parameters CME For Authors Journal Info
Skip Navigation LinksHome > January 2004 - Volume 100 - Issue 1 > Perioperative β-Adrenergic Receptor Blockade: Physiologic Fo...
Anesthesiology:
Clinical Concepts and Commentary

Perioperative β-Adrenergic Receptor Blockade: Physiologic Foundations and Clinical Controversies

London, Martin J. M.D.*; Zaugg, Michael M.D., D.E.A.A.†; Schaub, Marcus C. M.D., Ph.D.‡; Spahn, Donat R. M.D., F.R.C.A.§

Free Access
Article Outline
Collapse Box

Author Information

THE recent focus on perioperative β-adrenergic receptor blockade (PBB) to reduce cardiac morbidity or mortality follows nearly 40 yr of research documenting the cardioprotective effects of β-adrenergic receptors (BARs). On the basis of two influential randomized controlled trials demonstrating improvement in perioperative (30-day) or long-term (1- to 2-yr) outcome in high-risk patients, this practice is now routinely recommended by consultants and has recently been highlighted as a “top-tier” patient safety practice by the Institute of Medicine. 1 As such, it may serve as a performance measure for quality improvement. However, many aspects remain controversial. 2
This commentary examines physiologic concepts and potential uses of PBB in patients undergoing noncardiac surgery. Given well-documented difficulties with guideline compliance for β blockade after acute myocardial infarction (MI) (secondary prevention), it is to be expected that similar attempts in the large pool of eligible perioperative patients will require substantial ongoing efforts.
Back to Top | Article Outline

The Problem of Perioperative Cardiac Morbidity

Perioperative cardiac morbidity and mortality exact a substantial human toll and consume constrained economic resources. Their magnitude and costs are controversial, particularly in the general surgical population, given the variability in diagnosis and coding of outcomes. However, they are largely considered to be preventable with appropriate risk stratification, selective use of myocardial revascularization, and appropriate cardioprotective therapies, such as PBB. 3
Since the 1970s, the timing and character of perioperative myocardial infarction (PMI) reported in the literature has shifted from a predominance of Q-wave MI peaking between postoperative days 2 and 3 with a high mortality (25–50%) to earlier-occurring non–Q-wave MI with lower mortality. 4 PMI is closely associated with sustained elevation of heart rate, an absence of chest pain, and prolonged premonitory episodes of ST-segment depression before overt MI.
Perioperative hypothermia, anemia, increase of circulating catecholamines, and endogenous vasoconstrictors are etiologic factors. Abnormal endothelial function due to acute inflammatory responses is a well-recognized factor in the medical setting but is poorly characterized in the surgical setting. Easily inducible myocardial ischemia on provocative testing is strongly predictive of PMI. Impaired ventricular function markedly increases risk, likely because of reduction in coronary perfusion pressure. Asymptomatic perioperative troponin leaks may identify patients who are at increased risk in the first 6–24 months postoperatively. 5
Back to Top | Article Outline
Cardiovascular Effects of β Blockade
Fig. 1
Fig. 1
Image Tools
The impact of PBB on myocardial oxygen balance depends on complex interactions between supply-and-demand variables, anatomic factors (e.g., coronary stenoses, myocardial function), and the physiologic milieu (fig. 1).
The major salutary effects are reductions in heart rate (increasing diastolic perfusion time) and contractility (reducing oxygen demand). Diastolic time is curvilinearly related to heart rate, increasing rapidly below 75beats/min. As left ventricular coronary perfusion occurs predominantly during diastole, coronary blood flow increases, particularly distal to coronary stenoses and in the metabolically active subendocardium. Reducing heart rate directly decreases oxygen demand via reversal of the Bowditch-Treppe effect (e.g., increasing contractility with increasing heart rate). Maintenance of adequate coronary perfusion pressure is also important. Reduction in contractility reduces demand but may increase end-diastolic pressure in the failing ventricle. Low-dose β blockade for angina pectoris has modest effects on blood pressure in euvolemic medical patients. In surgical patients receiving sympatholytic therapies, greater reduction is likely.
Amelioration of ischemia distal to a critical stenosis is also influenced by the collateral circulation. The effects of β blockade on it remain controversial. Little change in regional blood flow may occur because of an overall reduction in oxygen demand. β Blockers have little influence on the primary variables influencing plaque vulnerability (e.g., lipid accumulation, inflammation, matrix degradation, and others). However, they reduce mechanical stress via hemodynamic effects, and clinical data support protective associations, particularly in patients with left ventricular hypertrophy. 6 Patients with dyslipidemias, glucose intolerance, and obesity have higher rates of recurrent plaque rupture predisposing to sudden death. 7
β Blockers have potent antiarrhythmic effects, particularly in the setting of acute ischemia. Reduction in circulating free fatty acids via inhibition of lipolysis may protect against ventricular fibrillation. They reduce sudden cardiac death in patients with congestive heart failure (CHF). Their prophylactic properties and enhanced rate control in atrial dysrhythmias are beneficial perioperatively.
Back to Top | Article Outline
Autonomic Nervous System and Receptor Physiology
Membrane-bound BARs (β1, β2, and the inhibitory β3 receptor) interact with agonists to mediate signal transduction. Physiologic specificity is modulated by a variety of protein kinases. 8 Stimulation of the mitogen-activated protein kinase signaling cascade affects gene transcription, inducing cardiac hypertrophy and apoptosis. Sustained agonist stimulation causes receptor desensitization via phosphorylation within minutes. Prolonged desensitization may occur with receptor sequestration. Human myocardium relies on BAR stimulation (predominantly β1) to increase contractility during stress. Changes in receptor type, density, and sensitivity with CHF markedly reduce myocardial adrenergic signal transduction capability. Antagonism of excessive BAR stimulation increases this and thus forms the basis for primary treatment of CHF. 9
Receptor physiology with myocardial ischemia is controversial given the heterogeneity of coronary syndromes. Increases in systemic concentrations and regional accumulation of catecholamines during acute MI likely facilitates myocardial necrosis. BAR density may increase acutely, causing supersensitivity that precipitates ventricular fibrillation. Complex interactions between β and α receptors are now appreciated. Imbalance in α- and β-adrenergic signaling due to concurrent receptor polymorphisms has recently been identified as a risk factor for CHF. 10
Perioperative studies document acute BAR desensitization in peripheral lymphocytes up to a week postoperatively, variably associated with sympathetic activation. Acute β blockade before cardiopulmonary bypass may protect ventricular function by inhibiting receptor desensitization. However, further research is needed to confirm that acute PBB uniformly protects ventricular function in the perioperative period.
Back to Top | Article Outline
Other Physiologic Effects of β Blockade
The anesthesia-sparing effects of PBB have been exploited clinically. In elderly men undergoing abdominal surgery, perioperative atenolol reduced hemodynamic lability, facilitated faster recovery, and lowered analgesic requirements. 11 However, direct effects on hemodynamics versus a true effect on anesthetic requirement remain controversial. Lipophilic β blockers readily cross the blood–brain barrier and have traditionally been implicated in central nervous system side effects. However, recent data cast doubt on the specificity and magnitude of these effects. β Blockers may alter memory encoding for and impart neuroprotective effects during cerebral ischemia as well. 8
Back to Top | Article Outline
Critical Analysis of the Major Randomized Controlled Trials
Not until the 1990s, when enhanced perioperative or long-term survival were reported, did PBB enter the realm of evidence-based medicine. 2 However, limited physiologic data collection, most notably, markers of the stress response or delineation of ventricular function, have frustrated attempts to determine casual mechanisms for the benefits observed.
The studies of Mangano et al.12 and Poldermans et al.13 have generated the most interest and debate. The latter is less controversial given its highly selected cohort (vascular patients with inducible ischemia) likely explaining the observed 90% relative reduction in 30-day outcome. Nonetheless, a lack of blinding, use of a standard care comparison, and an unexpectedly high mortality rate from PMI are problematic. A retrospective analysis of the screened cohort (1,351 patients), correlating clinical predictors, dobutamine stress echo results, and β blocker use (primarily long-term oral use with only 5% specifically treated acutely) with clinical outcomes, suggests that patients receiving any β blocker accrued benefit as the number of clinical predictors or new wall motion abnormalities increased. 14 However, the protective effect was negligible in the highest-risk patients, most of whom underwent surgical revascularization. Identifying (and treating) the latter group remains controversial, although the presence of three or more revised cardiac risk index predictors is recommended as a threshold to institute provocative testing. 2 The efficacy of PBB in this retrospective analysis remains controversial given the low overall event rate (3.3%) and uncertainty of the “intensity” of PBB. Other observational studies reporting associations of long-term oral therapy alone with outcome have not shown significant benefits.
The efficacy of long-term PBB in the cohort of Poldermans et al.15 was confirmed by prospective follow-up. Whether long-term use is efficacious in all vascular patients in the absence of other American College of Cardiology/American Heart Association (ACC/AHA) guideline criteria is uncertain. It seems that compliance with multiple guideline parameters is needed to ensure long-term survival. 16
The study of Mangano et al. is more controversial given a wider variety of patients and procedures studied, limited risk stratification, an earlier time frame before ambulatory or laparoscopic surgery or use of aggressive pain control and regional analgesia, the use of a single hospital, potential imbalances in patient risk between groups, lack of consideration of subsequent surgical procedures, and other factors. 12 They observed a striking reduction in long-term outcome (approximately 65% relative risk reduction, primarily in the first year) in the absence of a difference in perioperative outcome. This occurred despite a significantly greater amount of early postoperative myocardial ischemia on ambulatory ST-segment monitoring in patients who received placebo, a finding inconsistent with earlier reports from this group of a very strong association of postoperative ischemia with early PMI. 17 It has been speculated that inadequate statistical power or unexplained physiologic mechanisms (e.g., increased catecholamine concentrations leading to delayed rupture of coronary plaques) may be responsible. Multivariate analysis revealed only two significant variables associated with long-term survival: diabetes (adverse) and atenolol therapy (protective). 12 However, evaluation of subgroups of clinical interest (known coronary artery disease [CAD]vs. risk factors only, vascular vs. other types of surgery, and others) is problematic because of the limited sample size. Effects of sex were not evaluated (all-male cohort), nor was regional anesthesia or analgesia. Given these limitations, ACC/AHA guidelines accord PBB use in this type of cohort a class IIa recommendation in contrast to class I for patients meeting the entry criteria of Poldermans. 3 However, because this protocol is logistically simpler, it is appealing to a wide variety of settings.
An intriguing observation is the small difference in mean heart rates between treated and placebo (Mangano et al.12) or standard care (Poldermans et al.13) groups, on the order of 10–15 beats/min (depending on the time period reported), ranging from the low 70s to the mid to high 80s. This contrasts with earlier studies indicating that heart rates of greater than 100 beats/min are most predictive of ischemia. If the prevailing hypothesis linking ischemic episodes, heart rate, and ultimate outcome is correct, identifying patients based on maintenance of a group mean (e.g., target) heart rate alone does not seem possible. Raby et al.18 have suggested that identification of the preoperative ischemic threshold on ambulatory monitoring is possible. However, this approach is logistically difficult if not impossible. The observation that 35% of atenolol-treated patients in the cohort of Mangano et al. had intraoperative tachycardia suggests that a longer period of preoperative therapy, more aggressive dosing, or additional anesthetic interventions were required. 17
The interaction of PBB with regional anesthesia or analgesia has not been well characterized, despite epidural use (type and duration unspecified) in 40% of patients in the cohort of Poldermans et al. Given the strong interest in cardioprotective effects of regional anesthesia (particularly by the thoracic epidural route), this warrants further investigation.
It has been suggested that PBB may decrease subclinical cardiac troponin (I or T) release, leading to improved long-term outcome. 11 However, limited perioperative and percutaneous coronary intervention data are inconclusive or conflicting. 5
It can be argued that given strong efficacy in secondary prevention after MI, additional perioperative studies are unnecessary. That short-term PBB is beneficial or neutral in patients with known CAD is not controversial. In many centers, increasing percentages of patients present on long-term therapy because of better compliance with ACC/AHA guidelines. Although not all are adequately β blocked, most can be easily treated with routine anesthetic care and low-dose intravenous supplementation.
There is greater controversy in the larger group of patients with CAD risk factors only, in whom the number needed to treat to achieve a beneficial effect is a major concern. Numbers needed to treat ranging from only 3.2 for Poldermans et al. to 8.3 for Mangano et al. for mortality or PMI are strikingly lower than a recent meta-analysis estimate of 42 for secondary prevention after MI (2-yr mortality). 2,19 Specific numbers needed to treat for the risk factor–only group were not reported and are likely to be substantially greater.
Back to Top | Article Outline
Logistics of Perioperative β Blockade
Few patients have absolute contraindications to PBB. Although older literature warns against use with any degree of reactive airway disease (e.g., precipitation of bronchospasm), insulin-dependent diabetes (e.g., masking signs of hypoglycemia), and even peripheral vascular disease (e.g., increase in peripheral vascular resistance due to unopposed α-adrenergic vasoconstriction), newer data suggest that careful titration of β1-selective agents is tolerated in many of these patients. 20 However, severe asthma or a strong reactive component with chronic obstructive lung disease remain strong contraindications, as does major conduction disease (in the absence of a pacemaker) and previous documented sensitivities. In some patients, other sympatholytic therapies, including α2 agonists or continuous regional techniques, may be considered. Patients with compensated CHF may tolerate PBB, although it should be instituted gradually before surgery in accordance with ACC/AHA CHF guidelines. Judicious intravenous supplementation is usually well tolerated, especially during periods of adrenergic stimulation. Patients with isolated diastolic dysfunction are less problematic.
Increased vigilance is indicated in elderly patients given the reduction in maximal heart rate responses, lower resting heart rate, reduced ventricular compliance, and other physiologic changes of aging. Racial variation in response to β blockade has been reported as a result of genetic polymorphism of receptors or enzyme systems. Blacks may respond less favorably to treatment for CHF or hypertension (but not for CAD). Debrisoquin oxidation polymorphisms of metoprolol in Asian populations are common. There is little evidence for sex-specific effects.
Acute PBB with hypovolemia or sepsis is potentially hazardous. Patients receiving long-term therapy, especially with normal ventricular function, tolerate moderate degrees of hypovolemia well. Responses in patients with impaired ventricular function or concurrent regional sympathectomy are likely to be inadequate. A potential clinical strategy is to use esmolol after the period of major bleeding and after restitution of blood or plasma volume.
Secondary prevention studies have not documented differences in outcomes between agents with varying receptor selectivity or lipophilicity (so-called class differences), with the exception of an adverse association in agents with intrinsic sympathomimetic activity. 19 However, PBB should be instituted using β1-selective agents (e.g., atenolol, metoprolol, bisoprolol) given a lower potential for side effects at routine clinical doses. With increasing dosage, receptor selectivity is lost.
The ACC/AHA Perioperative Guidelines Committee limits specific recommendations to use in patients with inducible ischemia, starting days to weeks before surgery, titrated to a resting heart rate from 50–60 beats/min preoperatively. 3 No specific recommendations are made for lower-risk patients or for intraoperative or postoperative therapy.
Preoperative oral therapy may allow assessment of tolerance to therapy and take advantage of cellular-level effects (manifested via effects on gene transcription). 8 However, this remains speculative, and there are no data showing that acute PBB is less effective or less safe. Resting heart rate alone is an imprecise marker of β blockade, which is most accurately assessed by response to exercise or direct adrenergic challenge. Therefore, some patients may need substantial intravenous supplementation.
Institution of PBB before induction of anesthesia may not be required if hemodynamics are well controlled. This contrasts to emergence when ischemia is particularly common. Provision of the most aggressive therapy during the first 48–72 h postoperatively is likely to provide maximal benefit. The adequacy of pain control and other physiologic abnormalities (e.g., fever, anemia) are important variables in the duration of therapy. It is reasonable for therapy in low- to moderate-risk cohorts to be continued for the first week postoperatively, whereas patients undergoing vascular surgery, with its higher event rate, are likely better treated with therapy for 14–30 days postoperatively.
Ideally, oral therapy should be tapered before discontinuation to minimize hyperadrenergic withdrawal responses. Well documented in the medical literature, these are infrequently reported perioperatively, likely because of the short duration of treatment and the low doses used. Tapering is not usually required for doses of less than 25 mg oral atenolol (or its equivalent).
Adequate systemic blood pressure must be maintained. A systolic pressure of 100 mmHg or greater is recommended, although higher pressures are required in older or compromised patients. Studies have reported acceptable levels of hemodynamic side effects (primarily bradycardia and hypotension requiring transient treatment). However, safety data in specific subgroups, particularly with high levels of sympathetic blockade, major blood loss, advanced age, or other cardiac medications, have not been well delineated.
Careful attention is required when using atenolol in patients with renal insufficiency, particularly with repeated intravenous dosing, given its exclusive renal elimination and long half-life. Bisoprolol, metabolized by hepatic and renal routes, is not available intravenously and therefore is less problematic.
Finally, the perioperative period offers a unique opportunity for anesthesiologists to enhance compliance with ACC/AHA treatment guidelines for β blocker use (e.g., ischemic heart disease, CHF, and dysrhythmias). Therefore, reasonable attempts should be made to facilitate continuation of therapy in appropriate patients to maximize long-term survival.
Back to Top | Article Outline

Conclusions

Fig. 2
Fig. 2
Image Tools
Evidence for the efficacy of PBB is strong, and new physiologic and clinical data continue to accumulate. Epidemiologic studies provide a framework for the clinician to apply new physiologic principles in patients with known CAD and those at risk, particularly those with diabetes and left ventricular hypertrophy. Within the larger paradigm of perioperative sympatholysis, the logistics of PBB are influenced by patient risk, the planned surgical procedure, and the specifics of perioperative management (fig. 2). Established clinical guidelines of the ACC/AHA should be used to guide the institution and maintenance of therapy in appropriate patients. Results from several recently launched large-scale trials should ultimately refine our use of this simple but powerful therapy.
Back to Top | Article Outline

References

1. Shojania KG, Duncan BW, McDonald KM, Wachter RM: Safe but sound: Patient safety meets evidence-based medicine. JAMA 2002; 288: 508–13

2. Auerbach AD, Goldman L: β-Blockers and reduction of cardiac events in noncardiac surgery: Scientific review. JAMA 2002; 287: 1435–44

3. Eagle KA, Berger PB, Calkins H, Chaitman BR, Ewy GA, Fleischmann KE, Fleisher LA, Froehlich JB, Gusberg RJ, Leppo JA, Ryan T, Schlant RC, Winters WL Jr, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Jacobs AK, Hiratzka LF, Russell RO, Smith SC Jr: ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery: Executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation 2002; 105: 1257–67

4. Badner NH, Knill RL, Brown JE, Novick TV, Gelb AW: Myocardial infarction after noncardiac surgery. A nesthesiology 1998; 88: 572–8

5. Kim LJ, Martinez EA, Faraday N, Dorman T, Fleisher LA, Perler BA, Williams GM, Chan D, Pronovost PJ: Cardiac troponin I predicts short-term mortality in vascular surgery patients. Circulation 2002; 106: 2366–71

6. Heidland UE, Strauer BE: Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001; 104: 1477–82

7. Burke AP, Kolodgie FD, Farb A, Weber DK, Malcom GT, Smialek J, Virmani R: Healed plaque ruptures and sudden coronary death: Evidence that subclinical rupture has a role in plaque progression. Circulation 2001; 103: 934–40

8. Zaugg M, Schaub MC, Pasch T, Spahn DR: Modulation of beta-adrenergic receptor subtype activities in perioperative medicine: Mechanisms and sites of action. Br J Anaesth 2002; 88: 101–23

9. Bristow MR: β-Adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101: 558–69

10. Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB: Synergistic polymorphisms of β1- and α2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002; 347: 1135–42

11. Zaugg M, Tagliente T, Lucchinetti E, Jacobs E, Krol M, Bodian C, Reich DL, Silverstein JH: Beneficial effects from β-adrenergic blockade in elderly patients undergoing noncardiac surgery. A nesthesiology 1999; 91: 1674–86

12. Mangano DT, Layug EL, Wallace A, Tateo I: Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery: Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 1996; 335: 1713–20

13. Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blankensteijn JD, Baars HF, Yo TI, Trocino G, Vigna C, Roelandt JR, van Urk H, Fioretti PM, Paelinck B: The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N Engl J Med 1999; 341: 1789–94

14. Boersma E, Poldermans D, Bax JJ, Steyerberg EW, Thomson IR, Banga JD, van De Ven LL, van Urk H, Roelandt JR: Predictors of cardiac events after major vascular surgery: Role of clinical characteristics, dobutamine echocardiography, and beta-blocker therapy. JAMA 2001; 285: 1865–73

15. Poldermans D, Boersma E, Bax JJ, Thomson IR, Paelinck B, van de Ven LL, Scheffer MG, Trocino G, Vigna C, Baars HF, van Urk H, Roelandt JR: Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery. Eur Heart J 2001; 22: 1353–8

16. Mukherjee D, Lingam P, Chetcuti S, Grossman PM, Moscucci M, Luciano AE, Eagle KA: Missed opportunities to treat atherosclerosis in patients undergoing peripheral vascular interventions: Insights from the University of Michigan Peripheral Vascular Disease Quality Improvement Initiative (PVD-QI2). Circulation 2002; 106: 1909–12

17. Wallace A, Layug B, Tateo I, Li J, Hollenberg M, Browner W, Miller D, Mangano DT: Prophylactic atenolol reduces postoperative myocardial ischemia. McSPI Research Group. A nesthesiology 1998; 88: 7–17

18. Raby KE, Brull SJ, Timimi F, Akhtar S, Rosenbaum S, Naimi C, Whittemore AD: The effect of heart rate control on myocardial ischemia among high-risk patients after vascular surgery. Anesth Analg 1999; 88: 477–82

19. Freemantle N, Cleland J, Young P, Mason J, Harrison J: β Blockade after myocardial infarction: Systematic review and meta regression analysis. BMJ (Clin Res Ed) 1999; 318: 1730–7

20. Salpeter SR, Ormiston TM, Salpeter EE: Cardioselective beta-blockers in patients with reactive airway disease: A meta-analysis. Ann Intern Med 2002; 137: 715–25

Cited By:

This article has been cited 60 time(s).

Annales Francaises D Anesthesie Et De Reanimation
Preoperative betablockers use in vascular and thoracic surgery
Geeraerts, T; Albaladejo, P; Beloeil, H; Wernet, A; Bocquet, R; Castier, Y; Marty, J
Annales Francaises D Anesthesie Et De Reanimation, 23(8): 804-810.
10.1016/j.annfar.2004.06.007
CrossRef
Journal of Pharmacology and Experimental Therapeutics
beta-adrenergic blockade affects initial drug distribution due to decreased cardiac output and altered blood flow distribution
Avram, MJ; Krejcie, TC; Henthorn, TK; Niemann, CU
Journal of Pharmacology and Experimental Therapeutics, 311(2): 617-624.
10.1124/jpet.104.070094
CrossRef
European Journal of Vascular and Endovascular Surgery
The effect of perioperative beta-blockade on the pulmonary function of patients undergoing major arterial surgery
Kieran, SM; Cahill, RA; Browne, I; Sheehan, SJ; Mehigan, D; Barry, MC
European Journal of Vascular and Endovascular Surgery, 32(3): 305-308.
10.1016/j.ejvs.2006.02.015
CrossRef
Annales Francaises D Anesthesie Et De Reanimation
Betablockers in perioperative period: Drop the bombshell
Piriou, V; Marret, E; Albaladejo, P; Samain, E
Annales Francaises D Anesthesie Et De Reanimation, 27(3): 197-199.
10.1016/j.annfar.2008.01.002
CrossRef
Anaesthesist
Perioperative pharmacological myocardial protection. Systematic literature-based process optimization
Petzoldt, M; Kahler, J; Goetz, AE; Friederich, P
Anaesthesist, 57(7): 655-+.
10.1007/s00101-008-1396-9
CrossRef
Hospital Medicine
Preoperative evaluation of cardiac risk
Older, P; Hall, A
Hospital Medicine, 66(8): 452-457.

Annales Francaises D Anesthesie Et De Reanimation
Preoperative management of chronic medications
Baillard, C
Annales Francaises D Anesthesie Et De Reanimation, 24(): 1360-1374.
10.1016/j.annfar.2005.06.013
CrossRef
Anaesthesia and Intensive Care
The efficacy of landiolol for suppressing the hyperdynamic response following laryngoscopy and tracheal intubation: a systematic review
Inoue, S; Tanaka, Y; Kawaguchi, M; Furuya, H
Anaesthesia and Intensive Care, 37(6): 893-902.

Journal of Anesthesia
Possible indications of beta-blockers in the perioperative period other than prevention of cardiac ischemia
Kadoi, Y; Saito, S
Journal of Anesthesia, 24(1): 81-95.
10.1007/s00540-009-0865-x
CrossRef
Anaesthesist
Strategies for perioperative sympatho-modulation
Wacker, J; Pasch, T; Schaub, MC; Zaugg, M
Anaesthesist, 54(4): 303-318.
10.1007/s00101-005-0826-1
CrossRef
Anesthesia and Analgesia
Quo vadis, perioperative beta blockade? Are you "POISE'd" on the brink?
London, MJ
Anesthesia and Analgesia, 106(4): 1025-1030.
10.1213/ane.0b013e3181684af6
CrossRef
British Journal of Anaesthesia
Sinus node dysfunction associated with discontinuation of cilostazol in a patient taking atenolol
Ishiyama, T; Oguchi, T; Yamaguchi, T; Kumazawa, T
British Journal of Anaesthesia, 93(3): 472.
10.1093/bja/aeh602
CrossRef
Anaesthesia
Peri-operative myocardial ischaemia
Ackroyd, CR; Milner, QJW
Anaesthesia, 60(7): 714-715.

Minerva Anestesiologica
Risks, benefits, alternatives and indications of allogenic blood transfusions
Madjdpour, C; Heindl, V; Spahn, DR
Minerva Anestesiologica, 72(5): 283-298.

British Journal of Anaesthesia
Influence of continuous perioperative beta-blockade in combination with phosphodiesterase inhibition on haemodynamics and myocardial ischaemia in high-risk vascular surgery patients
Suttner, S; Boldt, J; Mengistu, A; Lang, K; Mayer, J
British Journal of Anaesthesia, 102(5): 597-607.
10.1093/bja/aep062
CrossRef
Irbm
2009 Update on Beta-blockers in the Prevention of Peri-operative Myocardial Infarction
Piriou, V; Vichova, Z
Irbm, 30(): S52-S57.

Anesthesiology
A large trial is vital to prove perioperative beta-blockade effectiveness and safety before widespread use
Leslie, K; Devereaux, PJ
Anesthesiology, 101(3): 803-804.

Mount Sinai Journal of Medicine
Preoperative Evaluation of Hospitalized Patients
Sigworth, SK
Mount Sinai Journal of Medicine, 75(5): 442-448.
10.1002/msj.20073
CrossRef
Journal of Cardiothoracic and Vascular Anesthesia
Recent Progress in Heart Failure Treatment and Heart Transplantation
Augoustides, JGT; Riha, H
Journal of Cardiothoracic and Vascular Anesthesia, 23(5): 738-748.
10.1053/j.jvca.2009.06.009
CrossRef
Canadian Journal of Anaesthesia-Journal Canadien D Anesthesie
Landiolol attenuates tachycardia in response to endotracheal intubation without affecting blood pressure
Yamazaki, A; Kinoshita, H; Shimogai, M; Fujii, K; Nakahata, K; Hironaka, Y; Iranami, H; Hatano, Y
Canadian Journal of Anaesthesia-Journal Canadien D Anesthesie, 52(3): 254-257.

Anasthesiologie & Intensivmedizin
Adrenergic receptors - Current knowledge and their importance for the perioperative phase
Lier, H; Schroder, S; Stuber, F
Anasthesiologie & Intensivmedizin, 48(): 7-+.

British Journal of Anaesthesia
Meta-analysis of the effect of heart rate achieved by perioperative beta-adrenergic blockade on cardiovascular outcomes
Biccard, BM; Sear, JW; Foex, P
British Journal of Anaesthesia, 100(1): 23-28.
10.1093/bja/aem331
CrossRef
Journal of Clinical Anesthesia
Preoperative beta-blocker use: impact of national guidelines on clinical practice
Akhtar, S; Assaad, S; Amin, M; Holt, NF; Barash, PG; Silverman, DG
Journal of Clinical Anesthesia, 20(2): 122-128.
10.1016/j.jclinane.2007.09.012
CrossRef
Anaesthesia, Pain, Intensive Care and Emergency: A.P.I.C.E
Use and misuse of preoperative cardiac testing for noncardiac surgery
Priebe, HJ
Anaesthesia, Pain, Intensive Care and Emergency: A.P.I.C.E, (): 269-278.

Journal of Anesthesia
Landiolol has a less potent negative inotropic effect than esmolol in isolated rabbit hearts
Ikeshita, K; Nishikawa, K; Toriyama, S; Yamashita, T; Tani, Y; Yamada, T; Asada, A
Journal of Anesthesia, 22(4): 361-366.
10.1007/s00540-008-0640-4
CrossRef
Presse Medicale
Management of coronary risk patients before anesthesia
Piriou, V
Presse Medicale, 38(): 1110-1119.
10.1016/j.lpm.2008.08.013
CrossRef
Annales Francaises D Anesthesie Et De Reanimation
Preoperative cardiac assessment using dobutamine stress echocardiography
Raux, M; Godet, G; Fine, E; Isnard, R
Annales Francaises D Anesthesie Et De Reanimation, 25(4): 386-396.
10.1016/j.annfar.2005.11.026
CrossRef
Minerva Anestesiologica
Influence of beta-blockers on the outcome of at risk patients
Priebe, HJ
Minerva Anestesiologica, 75(5): 319-323.

Anaesthesia
Ideal peri-operative management of patients with cardiovascular disease: the quest continues
Thompson, DJP
Anaesthesia, 59(5): 417-421.

British Journal of Anaesthesia
Sympatho-modulatory therapies in perioperative medicine
Zaugg, M; Schulz, C; Wacker, J; Schaub, MC
British Journal of Anaesthesia, 93(1): 53-62.
10.1093/bja/aeh158
CrossRef
British Journal of Anaesthesia
Perioperative myocardial infarction - aetiology and prevention
Priebe, HJ
British Journal of Anaesthesia, 95(1): 3-19.
10.1093/bja/aei063
CrossRef
Anasthesiologie & Intensivmedizin
Perioperative medical management of cardiac patients
Priebe, HJ
Anasthesiologie & Intensivmedizin, 51(): 232-249.

Journal of Clinical Anesthesia
Preoperative beta-blocker use: is titration to a heart rate of 60 beats per minute a consistently attainable goal?
Akhtar, S; Amin, M; Tantawy, H; Senior, A; Barash, PG; Silverman, DG
Journal of Clinical Anesthesia, 17(3): 191-197.
10.1016/j.jclinane.2004.06.020
CrossRef
Journal of Clinical Anesthesia
The effect of clonidine on perioperative blood coagulation
Ganter, MT; Hofer, CK; Spahn, DR; Bruggisser, M; Bombeli, T; Seifert, B; Pasch, T; Zalunardo, MP
Journal of Clinical Anesthesia, 17(6): 456-462.
10.1016/j.jclinane.2004.11.004
CrossRef
Journal of Cardiothoracic and Vascular Anesthesia
Perioperative pharmacologic cardioprotection and sodium hydrogen ion exchange inhibitors: One step forward and two steps back?
London, MJ; Henderson, WG
Journal of Cardiothoracic and Vascular Anesthesia, 19(5): 565-569.
10.1053/j.jvca.2005.07.027
CrossRef
Cleveland Clinic Journal of Medicine
Perioperative beta-blockers in noncardiac surgery: Evolution of the evidence
Harte, B; Jaffer, AK
Cleveland Clinic Journal of Medicine, 75(7): 513-519.

Annales Francaises D Anesthesie Et De Reanimation
Anaesthetic-induced myocardial preconditioning: fundamental basis and clinical implications
Chiari, P; Bouvet, F; Piriou, V
Annales Francaises D Anesthesie Et De Reanimation, 24(4): 383-396.
10.1016/j.annfar.2005.01.020
CrossRef
Anasthesiologie & Intensivmedizin
Current status of perioperative beta blocker therapy in Germany - Results of a postal survey
Suttner, S; Boldt, J; Wolf, M; Papsdorf, M; Lang, K; Piper, S
Anasthesiologie & Intensivmedizin, 47(): 203-209.

Canadian Journal of Anaesthesia-Journal Canadien D Anesthesie
Review article: The role of statins in reducing perioperative cardiac risk: physiologic and clinical perspectives
Boushra, NN; Muntazar, M
Canadian Journal of Anaesthesia-Journal Canadien D Anesthesie, 53(): 1126-1147.

Annales Francaises D Anesthesie Et De Reanimation
Analgesia after hip fracture repair in elderly patients: the effect of a continuous femoral nerve block: a prospective and randomised study
Cuvillon, P; Ripart, J; Debureaux, S; Boisson, C; Veyrat, E; Mahamat, A; Bruelle, P; Viel, E; Eledjam, JJ
Annales Francaises D Anesthesie Et De Reanimation, 26(1): 2-9.
10.1016/j.annfar.2006.06.025
CrossRef
British Journal of Hospital Medicine
Preoperative evaluation of cardiac risk
Older, P; Hall, A
British Journal of Hospital Medicine, 66(8): 452-457.

Journal of General Internal Medicine
Lack of adherence with preoperative B-blocker recommendations in a multicenter study
Kolodner, DQ; Do, H; Cooper, M; Lazar, E; Callahan, M
Journal of General Internal Medicine, 21(6): 596-601.
10.1111/j.1525-1497.2006.00408.x
CrossRef
Anesthesia and Analgesia
Con: Beta-blockers are indicated for all adults at increased risk undergoing noncardiac surgery
London, MJ
Anesthesia and Analgesia, 104(1): 11-14.
10.1213/01.ane.0000231830.13665.05
CrossRef
Canadian Journal of Anaesthesia-Journal Canadien D Anesthesie
The effect of perioperative beta-blockers on patients undergoing noncardiac surgery - is the answer in?
Devereaux, PJ; Leslie, K; Yang, H
Canadian Journal of Anaesthesia-Journal Canadien D Anesthesie, 51(8): 749-+.

Surgical Clinics of North America
Perioperative issues: Myocardial ischemia and protection - Beta-blockade
Maggio, PM; Taheri, PA
Surgical Clinics of North America, 85(6): 1091-+.
10.1016/j.suc.2005.09.016
CrossRef
Anesthesia and Analgesia
Effect of postoperative analgesia on major postoperative complications: A systematic update of the evidence
Liu, SS; Wu, CL
Anesthesia and Analgesia, 104(3): 689-702.
10.1213/01.ane.0000255040.71600.41
CrossRef
Journal of Cardiothoracic and Vascular Anesthesia
Patient understanding of the importance of beta-blocker use in the perioperative period
Rosenfeld, DM; Trentman, TL; Hentz, JG; Hagstrom, SG; Demenkoff, JH
Journal of Cardiothoracic and Vascular Anesthesia, 21(3): 325-329.
10.1053/j.jvca.2007.02.001
CrossRef
Journal of Cardiovascular Pharmacology
Akrinor-induced Relaxation of Pig Coronary Artery In Vitro is Transformed into α1-Adrenoreceptor-mediated Contraction by Pretreatment With Propranolol
Usichenko, TI; Foellner, S; Gruendling, M; Feyerherd, F; Lehmann, C; Wendt, M; Pavlovic, D
Journal of Cardiovascular Pharmacology, 47(3): 450-455.
10.1097/01.fjc.0000211710.87863.89
PDF (160) | CrossRef
Anesthesiology
Is There Any Reason To Withhold β Blockers from High-risk Patients with Coronary Artery Disease during Surgery?
Kertai, MD; Bax, JJ; Klein, J; Poldermans, D
Anesthesiology, 100(1): 4-7.

PDF (371)
Anesthesiology
Genetic Modulation of Adrenergic Activity in the Heart and Vasculature: Implications for Perioperative Medicine
Zaugg, M; Schaub, MC
Anesthesiology, 102(2): 429-446.

PDF (832)
Anesthesiology
Does Preoperative Coronary Angioplasty Improve Perioperative Cardiac Outcome?
Godet, G; Riou, B; Bertrand, M; Fléron, M; Goarin, J; Montalescot, G; Coriat, P
Anesthesiology, 102(4): 739-746.

PDF (447)
Anesthesiology
Adrenergic Receptor Genotype but Not Perioperative Bisoprolol Therapy May Determine Cardiovascular Outcome in At-risk Patients Undergoing Surgery with Spinal Block: The Swiss Beta Blocker in Spinal Anesthesia (BBSA) Study: A Double-blinded, Placebo-controlled, Multicenter Trial with 1-Year Follow-up
Schulz, C; Hersberger, M; Kälin, G; Furrer, L; Hofer, C; Blumenthal, S; Müller, A; Zollinger, A; Spahn, DR; Borgeat, A; Zaugg, M; Bestmann, L; Wacker, J; Lucchinetti, E; Boltres, A
Anesthesiology, 107(1): 33-44.
10.1097/01.anes.0000267530.62344.a4
PDF (593) | CrossRef
Anesthesiology
Erratum

Anesthesiology, 101(2): 565.

PDF (40)
Anesthesiology
Why Should Primary Care Physicians Even Wait for Surgery in High Risk Patients?
Martin Kempen, P
Anesthesiology, 101(3): 801-802.

PDF (1009)
Anesthesiology
Solid (Concrete) Evidence Needs Both Cement and Sand
Basler, M; Daniel, M
Anesthesiology, 101(3): 802-803.

PDF (1009)
Anesthesiology
A Large Trial Is Vital to Prove Perioperative β-blockade Effectiveness and Safety before Widespread Use
London, MJ; Zaugg, M; Schaub, MC; Spahn, DR
Anesthesiology, 101(3): 804-805.

PDF (1009)
Anesthesiology
Takotsubo Cardiomyopathy after General Anesthesia for Eye Surgery
Gavish, D; Rozenman, Y; Hafner, R; Bartov, E; Ezri, T
Anesthesiology, 105(3): 621-623.

PDF (292)
Anesthesiology
Pragmatic Treatment versus Elaborative but Incomplete Testing: A Hobson’s Choice?
Spahn, DR; Chassot, P; Zaugg, M
Anesthesiology, 107(4): 526-529.
10.1097/01.anes.0000282095.72213.85
PDF (436) | CrossRef
Anesthesiology
Is There Any Reason to Withhold α2 Agonists from Patients with Coronary Disease during Surgery?
Quintin, L; Ghignone, M
Anesthesiology, 101(5): 1244.

PDF (881)
Critical Care Medicine
Vascular surgery critical care: Perioperative cardiac optimization to improve survival
Venkataraman, R
Critical Care Medicine, 34(9): S200-S207.
10.1097/01.CCM.0000231885.74567.4F
PDF (296) | CrossRef
Back to Top | Article Outline

© 2004 American Society of Anesthesiologists, Inc.

Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.
Login

Article Tools

Images

Share